LA JOLLA, CALIF (September 8,
2022)– Calidi
Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology
company that is pioneering allogeneic cell-based
platforms to revolutionize oncolytic virus therapies, today
announced that senior management will present a company overview at two
upcoming investor conferences:
- SALT New York 2022 on Monday, September 12, 2022 at 7:00
a.m. PT / 10:00 a.m ET; and
- Baird 2022 Global Healthcare Conference on Tuesday,
September 13, 2022 at 11:35 a.m. PT / 2:35 p.m. ET.
About Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage immuno-oncology company
with proprietary technology that is revolutionizing the effective delivery
and potentiation of oncolytic viruses for targeted therapy against
difficult-to-treat cancers. Calidi Biotherapeutics is advancing a potent
allogeneic stem cell and oncolytic virus combination for use in multiple
oncology indications. Calidi’s off-the-shelf, universal cell-based
delivery platforms are designed to protect, amplify, and potentiate
oncolytic viruses currently in development leading to enhanced efficacy and
improved patient safety. Calidi Biotherapeutics is headquartered in La
Jolla, California. For more information, please visit www.calidibio.com.
Contacts:
For Investors:
Stephen Jasper
stephen@gilmartinir.com